United States securities and exchange commission logo





                          May 24, 2023

       Julie Eastland
       President and Chief Executive Officer
       Harpoon Therapeutics, Inc.
       131 Oyster Point Blvd, Suite 300
       South San Francisco, CA 94080

                                                        Re: Harpoon
Therapeutics, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed May 19, 2023
                                                            File No. 333-272064

       Dear Julie Eastland:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Arzhang
Navai at 202-551-4676 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Marina Remennik